BioMed Central | Articles which cite: Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.

Log on / register
Feedback | Support | My details

home journals A-Z subject areas advanced search authors reviewers libraries about my BioMed Central

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.
Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters SA, Astry C, Aricó E, Zhao Y, Selleri S, Wang E, Marincola FM
Genome Biol 2007, 8:R8
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]

printer friendly

to [Help]

PubMed Central articles that cite the above article:

1.	GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. Selleri S, Deola S, Pos Z, Jin P, Worschech A, Slezak SL, Rumio C, Panelli MC, Maric D, Stroncek DF, Wang E, Marincola FM J Transl Med 2008, 6:17 [PubMed Central] [PubMed] [Related articles]
2.	Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH Cancer Res 2008 Apr 1, 68:2436-46 [PubMed Central] [PubMed] [Related articles]
3.	A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM J Transl Med 2008, 6:81 [PubMed Central] [PubMed] [Related articles]
4.	Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, Monsurró V, Buller RM, Stroncek DF, Wang E, Szalay AA, Marincola FM BMC Genomics 2009, 10:301 [PubMed Central] [PubMed] [Related articles]
5.	Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM J Transl Med 2009, 7:45 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 3 articles in BioMed Central

You can also check ISI Web of Science for additional citations (subscription required)

printer friendly

to [Help]

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us